The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Aduro Biotech
Stock and Other Ownership Interests - Aduro Biotech
Patents, Royalties, Other Intellectual Property - Stanford University School of Medicine
Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas.
 
Funda Meric-Bernstam
Honoraria - Dialectica; Sumitomo Group
Consulting or Advisory Role - Aduro Biotech; Clearlight Diagnostics; DarwinHealth; Debiopharm Group; Genentech; Inflection Biosciences; Mersana; Origimed; Pieris Pharmaceuticals; Samsung Bioepis; Spectrum Pharmaceuticals; Xencor
Research Funding - Abbvie; Aileron Therapeutics; AstraZeneca; Bayer; Boehringer Ingelheim (I); Calithera Biosciences; Curis; CytomX Therapeutics; Daiichi Sankyo; Debiopharm Group; eFFECTOR Therapeutics; Genentech; GlaxoSmithKline; Guardant Health (Inst); Jounce Therapeutics; Novartis; Pfizer; PUMA Biotechnology; Taiho Pharmaceutical; Zymeworks
 
Shahneen Kaur Sandhu
Honoraria - Amgen; Bristol-Myers Squibb; Merck; Merck Serono
Consulting or Advisory Role - Amgen
Speakers' Bureau - Bristol-Myers Squibb; Merck; Roche/Genentech
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Omid Hamid
Honoraria - Amgen; Array BioPharma; Bristol-Myers Squibb; Genentech/Roche; Novartis; Sanofi/Regeneron
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck; Novartis; Roche
Speakers' Bureau - Amgen; Array BioPharma; Bristol-Myers Squibb; Genentech; Novartis; Sanofi/Regeneron
Research Funding - Amgen (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); CytomX Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); MedImmune (Inst); Merck (Inst); Merck Serono (Inst); NextCure (Inst); Novartis (Inst); Parker Institute for Cancer Immunotherapy (Inst); Pfizer (Inst); Polynoma (Inst); Regeneron (Inst); Roche (Inst)
 
Anna Spreafico
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Novartis; Oncorus
Research Funding - AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Janssen Oncology; Merck; Northern Biologics; Novartis; Surface Oncology; Surface Oncology; Symphogen
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Idera; Merck
 
Stefan Kasper
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Merck Serono; MSD Oncology; Roche; Shire; Shire
Consulting or Advisory Role - Amgen; AstraZeneca; Baxalta; Bristol-Myers Squibb; Lilly; Merck Serono; MSD Oncology; Roche; Sanofi; SERVIER
Research Funding - Bristol-Myers Squibb; Celgene; Lilly; Merck Serono; SERVIER
Travel, Accommodations, Expenses - Amgen; Lilly; Merck Serono; Roche; Sanofi
Other Relationship - Amgen; Merck Serono; Sanofi
 
Reinhard Dummer
Honoraria - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Sanofi; Sun Pharma; Takeda
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Sanofi; Sun Pharma; Takeda
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)
 
Toshio Shimizu
Consulting or Advisory Role - Joint Scientific Committee Review Member for Phase 1 trails in Hong Kong; Millennium; The Consortium on Harmonisation of Institutional Requirements for Clinical Research- CHAIR
Speakers' Bureau - Boehringer Ingelheim; Chugai Pharma; Ono Pharmaceutical; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - 3D Medicines (Inst); Bristol-Myers Squibb (Inst); Chordia Therapeutics (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Five Prime Therapeutics (Inst); Lilly (Inst); Millennium (Inst); Novartis (Inst); PharmaMar (Inst); SymBio Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Takeda/Millennium
 
Neeltje Steeghs
Research Funding - AB Science (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Blueprint Medicines (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Deciphera (Inst); Genentech (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
 
Nancy Lewis
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Craig C. Talluto
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Sinead Dolan
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Andrew Bean
Employment - Novartis
 
Robert Brown
Employment - Aduro Biotech; Iovance Biotherapeutics
Stock and Other Ownership Interests - Iovance Biotherapeutics
 
Damian Trujillo
Employment - Aduro Biotech
Stock and Other Ownership Interests - Aduro Biotech
 
Nitya Nair
No Relationships to Disclose
 
Jason J. Luke
Stock and Other Ownership Interests - Actym Therapeutics
Consulting or Advisory Role - 7 Hills Pharma; Actym Therapeutics; Aduro Biotech; Alphamab; Amgen; Array BioPharma; AstraZeneca/MedImmune; Benevir; Bristol-Myers Squibb; Castle Biosciences; Checkmate Pharmaceuticals; Compugen; EMD Serono; Gilead Sciences; IDEAYA Biosciences; Janssen; Jounce Therapeutics; Mavu Pharmaceutical; Merck; Newlink Genetics; Novartis; Reflexion Medical; Spring Bank; Syndax; Tempest Therapeutics; TTC Oncology; Vividion Therapeutics; WntRx Pharmaceuticals
Research Funding - Abbvie (Inst); Array BioPharma; Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Checkmate Pharmaceuticals; Compugen (Inst); Corvus Pharmaceuticals (Inst); Delcath Systems (Inst); Evelo Therapeutics; Five Prime Therapeutics (Inst); FLX Bio; Genentech/Roche (Inst); Immunocore (Inst); Incyte (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Palleon Pharmaceuticals; Pharmacyclics (Inst); Tesaro (Inst); Xencor (Inst)
Patents, Royalties, Other Intellectual Property - Serial #15/612,657 (Cancer Immunotherapy),; Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)
Travel, Accommodations, Expenses - Amgen; Array BioPharma; AstraZeneca/MedImmune; Benevir; Bristol-Myers Squibb; Castle Biosciences; Checkmate Pharmaceuticals; EMD Serono; Gilead Sciences; IDEAYA Biosciences; Janssen; Jounce Therapeutics; Merck; Novartis; Reflexion Medical